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Abstract
Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or
nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property
to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent
kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally
protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the
kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid
and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA
effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3
fluorescence and in situ hybridization of siRNA corroborated a short t½ for siRNA. The extent of
renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose-
and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both
cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatin-induced
kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells
follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of
apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.
Acute kidney injury (AKI) is a clinically devastating disease associated with unacceptably high mortality
rates,  progression to end-stage renal disease,  and increasing incidence.  Recent attention has
focused on translating basic pathophysiologic understanding into clinical advances in an effort to
develop selective approaches mediating effective targeted therapeutic interventions.
Activation and upregulation of a number of different intracellular signaling cascades occurs during and
following cell injury from ischemia, trauma, toxins, or infections. These signaling cascades are involved
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with inflammation; apoptosis; and many other autocrine, paracrine, and endocrine events. Apoptosis
has been increasingly recognized as a central player in the pathophysiology of AKI,  and numerous
studies have documented the quantitative importance of apoptotic renal cell death in ischemia, sepsis,
and nephrotoxic injury.  Apoptosis develops along with inflammation, and the two processes
potentiate each other. Thus, many inflammatory cytokines and reactive oxygen species are known to
trigger apoptosis. The apoptotic program is highly conserved among species  and has been divided into
two distinct pathways: the intrinsic or mitochondrial, and the extrinsic or death ligand-mediated
pathways.  Both extrinsic and intrinsic pathways play a role in various forms of renal injury, and
the relative importance of each pathway varies with the specific injury model. The two pathways are
not completely independent and can potentiate each other.
The major epithelial cell type involved in animal models of AKI from ischemia, septic, and most
nephrotoxic insults is the proximal tubule cell (PTC). PTCs reabsorb many filtered molecules, and
intracellular processing can include metabolism, accumulating in lysosomes, release into the cytosol,
and transcytoses. Early experiments with antisense oligonucleotides, containing either phosphorothioate
or phosphodiester backbones, demonstrated their predominant excretion via glomeruli filtration, and
kidney accumulation was ascribed to tubular epithelial cell reabsorption.  Recent scintigraphic data
indicated that, like antisense oligonucleotides, siRNA administered intravenously also accumulated in
the kidney to greater than 40 times the level seen in any other organ. However, resolution at the
cellular level was not undertaken in this study.  Both antisense oligonucleotides and siRNA have been
shown to suppress activity of the target genes expressed in proximal tubular cells.  Suppression of
renal caspase 3 and 8  and C5a  have been shown to minimize ischemic injury. The potential
therapeutic opportunities utilizing RNAi in vivo are just now being recognized. Since delivery to and
uptake by target cells are prerequisites for efficacy, PTCs may offer unique and exciting opportunities for
in vivo utilization of RNAi technology in the treatment and/or prevention of diseases.
We and others have documented the importance of p53 activation in ischemia-reperfusion injury to the
kidney and other organs.  The apoptotic program triggered by p53 depends both on its
transcriptional activity and direct interactions with Bcl2 family members at the level of mitochondrial
membranes.  Therefore, we chose inhibition of p53 expression following ischemia-reperfusion
injury as a means to test the efficacy of siRNA in vivo in reducing PTC injury and improving organ
function.
Results
Proximal Tubule Reabsorption of siRNA
Initial studies evaluated kidney cell uptake of a Cy3-labeled siRNA following intravenous
administrations. Figure 1 (A through F) shows representative 2-photon images collected at 0 and 3 min
from the same MW (Munich Wistar) rat. Following intravenous (IV) injection, there was rapid
glomerular filtration of the Cy3-siRNA siRNA with subsequent proximal tubule brush border binding
and endocytosis by PTC. Within 3 min, extensive binding to the apical membrane had occurred and
early endosomes on the outer aspects of the apical membrane could be visualized (Figure 1, B through
D). The minimal Cy3-siRNA label in the vasculature at 3 min indicated rapid renal clearance. In 
Figure 1E, by sixty minutes postinjection, there was increased and now uniform labeling of the apical
membrane of PTC, and intense cellular internalization was seen with terminal web and lysosomal
localizations. Labeling of distal tubules, endothelial cells or circulating white blood cells was not seen. By
24 h (Figure 1F), there was nearly complete lack of the Cy3-siRNA in PTC. These extended time
observations were made in the same rat used for the 0 to 60 min studies.
Figure 2 shows quantitative threshold analysis to determine total cellular and cytosolic Cy3-siRNA in
PTC. Figure 2A shows an unmanipulated image, Figure 2B is the thresholded profiled image, and 
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Figure 2C is the subtraction analysis image of low-intensity value areas. The blue and purple areas
represent low-level “free” cytosolic labeling. Figure 2D shows the quantitative analysis revealing a rapid
increase, a plateau, and a rapid decline in both total and free cytosolic siRNA, with cytosolic siRNA
being at a level less than 200 times of total cellular siRNA. Rapid elimination of fluorescence signal
from both total and cytosolic siRNA occurred.
To confirm these fluorescence siRNA results, in situ hybridization studies were undertaken and siRNA
was identified in the vast majority of PTCs one hour after intravenous administration (Figure 3A).
However, at 24 h post-treatment, the hybridization signal was rarely detected (Figure 3B). The
specificity of detection of injected siRNA by in situ hybridization was confirmed by the lack of reaction
with a nonspecific probe (Figure 3C) in siRNA-treated or with the specific probe in siRNA-untreated
rats (Figure 3D).
Generation of p53 Targeting siRNA to Inhibit P53 Production
Synthetic siRNA targeting rat p53 mRNA (siP53), following transfection into cultured Rat1 cells
expressing wild-type p53, elicited near complete p53 mRNA elimination at a concentration of ∼1nM
with an IC50 of approximately 0.23nM (Figure 4A). p53 siRNA also inhibited P53 protein production
even at 0.5 nm concentrations (Figure 4B). Incubation of siRNA in 100% rat (not shown) or human
serum at 37 °C for 24 h did not result in any detectable degradation of the molecule (Figure 4C).
P53 siRNA Minimizes Ischemic Injury
To determine the effect of the p53 siRNA on the preservation of kidney function, bilateral renal-clamp
studies were undertaken (Figure 5). Initial studies utilizing four injections of p53 siRNA, with two
injections before (−2 h, −30 min) and two postinjury (+4 and 8 h), had indicated a protection of kidney
function and preservation of morphology (data not shown). With each injection, rats received either 1
mg/kg (cumulative dose −4 mg/kg) of p53 siRNA or GFP siRNA, or an equal volume of PBS. Baseline
creatinine increased from 0.2 ± 0.1 mg/dl to 3.7 ± 0.8 with ischemia (Figure 5A). The GFP siRNA had
no protective effect, whereas p53 siRNA reduced serum creatinine to 1.9 ± 0.2 (P < 0.01).
For dose-response analysis, rats were injected with doses of siP53, 0.33; 1, 3, or 5 mg/kg, given at the
same four time points, resulting in cumulative doses of 1.32; 4, 12, and 20 mg/kg, respectively (Figure 5
B). All siRNA doses tested produced a SCr reducing effect on day one with higher doses being effective
over approximately five days compared with PBS-treated ischemic control rats. The 12 and 20 mg/kg
cumulative doses provided the best protective effect.
Dose and Time Optimization for siRNA Effect
Twelve mg/kg siP53 dose was selected for dose optimization and time course studies (Figure 5C). P53
siRNA was effective when administered between 16 h before the clamping and 8 h after removal of the
clamp, with injections given at 2 and 4 h postinjury being most efficacious. Single 12 mg/kg dose at 2
and 4 h postinjury was more effective than the same dose administered in four injections spread over
time (P = 0.01, ANOVA). siRNA administration 12 h post-ischemic injury or 24 h before the clamp
were ineffective when compared with PBS-treated ischemic controls.
Next, dose-response studies for a single injection administered at the optimal 4-h time point were
undertaken (Figure 5D). All doses were effective in reducing serum creatinine (P < 0.01), and 12 mg/kg
siP53 dose administered at 4 h after clamp release was selected for further studies based on its efficacy
and cost considerations. Treatment with control siGFP (12 mg/kg 4 h postinjury) produced no
protective effect on serum creatinine. Also, serum creatinine remained at baseline for 9 wk following
P53 siRNA therapy in an AKI clamp-injury model (data not shown).
siRNA to p53 Minimized Histologic Injury and Apoptosis
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Semiquantitative histologic analysis was conducted on kidney specimens at 24 h postinjury to determine
the effectiveness of siP53 on preservation of tissue integrity (Figure 6A). Although tubular damage was
seen in all specimens, it was reduced in both cortical and outer medullary tissue (P < 0.05) with RNAi
therapy (Figure 6, A and B). In the medullary region there was also increased microvascular congestion
seen only in the PBS-treated ischemic kidneys.
We used a quantitative TUNEL assay to determine the effect of inhibiting p53 expression on epithelial
cell apoptosis in a thirty-minute bilateral clamp model. Figure 6C shows siP53 administration resulted
in a statistically significant reduction (P < 0.01) in TUNEL-positive nuclei in both cortical and
medullary tissue. The increased amount of apoptosis in the outer medulla, compared with the cortex, is
in agreement with previous studies.
siP53 Reduced Ischemia-Induced Upregulation of P53
P53 protein levels in PTCs are very low under baseline physiologic conditions and increase significantly
following ischemic injury beginning at 2 to 4 h peaking at 24 h postinjury.  Therefore, kidney tissues
were harvested at 24 h postinjury to evaluate the effect of the p53 siRNA on maximal p53 protein
expression following ischemic injury. P53 protein was not detectable in noninjured kidneys by Western
blotting (not shown). However, 24 h following injury, p53 protein was readily detectable in kidneys
from ischemic animals but not from those receiving 12 mg/kg siP53 4 h after reperfusion initiation (
Figure 7A). There was also a diminution in expression of p53-responsive pro-apoptotic gene PUMA as
previously reported  and another p53-dependent gene, MDM2.  In contrast, siP53 treatment did not
affect P21 protein expression induced by ischemia-reperfusion injury. Although p21 is considered a
classical p53-dependent transcription target, its upregulation in ischemic kidney injury has previously
been shown to be hypoxia- but not p53-dependent.  Moreover, hypoxic induction of p21 was
demonstrated to have a positive effect on the injury outcome.  Similar independence on p53 inhibition
by siRNA was detected for one additional p53-dependent, pro-apoptotic, protein NOXA (not shown)
that, like p21, loses p53 dependence under hypoxic conditions.  The observation of similar upregulation
of the hypoxia-dependent proteins P21 and NOXA in nontreated ischemic and siP53-treated rats
suggests an equivalent extent of injury-inducing stimuli was applied in treated and control groups.
Among other proteins tested, the anti-apoptotic protein BCL2 and tubulin, used as loading control, did
not show fluctuation in expression levels either in response to injury or in response to siP53.
To discriminate whether the observed inhibition of p53 protein expression in siP53-treated rats 24 h
after injury was a consequence of reduced injury or a result of siRNA-mediated inhibition of expression,
we analyzed p53 mRNA expression in kidneys following intravenous siRNA administration. As shown
in Figure 7B, siRNA-mediated reduction of p53 mRNA levels was detected at 3 and 6 h after siRNA
administration and returned to baseline levels between 24 and 48 h or between 6 and 24 h post IV
injection in the cortex and medulla, respectively. The apparent partial reduction of p53 mRNA observed
in the kidney may be explained by masking effects derived from p53 mRNA originating from multiple
kidney cell types that were not targeted by siRNA due to its selective uptake by PTCs.
siP53 Minimizes Hypoperfusion-Induced and Cisplatin Nephrotoxicity
To determine if inhibiting P53 protein expression is effective in other models of PTC injury, where P53
has been implicated as an important apoptotic factor,  we tested a hypoperfusion/ischemia model
and a cisplatin model of kidney injury. The results, as shown in Figure 8, indicate that P53 siRNA
minimized renal injury in both of these additional models. The partial aortic-clamp model was recently
characterized as a model more in line with reduced kidney perfusion as might occur during cardiac
bypass surgery.  The cisplatin model was characterized with daily detection of serum creatinine levels
postdrug injection (Figure 8B, top). This model is a progressive kidney injury model known to be
secondary to apoptosis-mediated cell injury. There was a progressive increase in serum creatinine over
the first five days following an intraperitoneal injection of cisplatin. In agreement with the limited
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duration of siP53-mediated gene knockdown in kidneys (see Figure 8B), renal protection evaluated 5 d
following cisplatin administration was dependent upon multiple daily doses of the siRNA. Specifically,
preservation of kidney function was only observed in animals that received doses of siRNA over the
course of the first three days following cisplatin administration (groups 4 and 5), whereas animals that
received a single dose siRNA around the time of cisplatin administration exhibited no protection (groups
2 and 3). siRNA against GFP was without effect in minimizing cisplatin-induced AKI (data not shown).
Taken together, these data indicate that siRNA designed to inhibit expression of P53 is effective in
minimizing AKI in chemotoxic and ischemic models where P53 is known to be an important regulator
of apoptosis in PTC.
Discussion
The results from our studies support the therapeutic potential of the temporary inhibition of p53
expression to protect cells from acute injury, and demonstrate that synthetic siRNAs represent an
effective means for eliciting such activity in the kidney following intravenous administration.
Effective therapeutic use of siRNA depends on the ability to specifically suppress expression of target
proteins contributing to the progression of injury or disease. However, it is essential that RNAi be
activated in the specific cell type at the optimal time. We show here that the kidney, and in particular
the proximal tubule epithelium, is a uniquely favorable target for synthetic siRNA accumulation
following intravenous administration. Furthermore, siRNA targeting p53 was effective at suppressing
the expression of p53 in these cells following ischemia-reperfusion and in limiting the resulting kidney
injury. Effective siRNA delivery and therapeutic efficacy were achieved without the need for either local
delivery into renal vessels, systemic hydrodynamic administration as attempted before,  or
complicated formulation with delivery-enhancing agents.
The use of intravital 2-photon fluorescence imaging, with the confirmation by in situ siRNA detection
using hybridization, provides insight into the spatial and temporal distribution of the siRNA. We show
this technique affords the spatial resolution to precisely localize the siRNA to specific cell types (Figure 1
), and the distribution of labeled siRNA in the kidney could be followed in the same animal over a time
scale (Figure 1), giving information about the rate of metabolism of the siRNA. In a previous study,
siRNA was found by scintigraphy to be concentrated in the kidney to levels 40-fold higher than other
organs. However, this study lacked the spatial and temporal resolution for a more mechanistic
understanding of this observation and used unmodified oligonucleotides with a phosphodiester
backbone, which are rapidly degraded by plasma ribonucleases.  Oligonucleotides used in this present
study were modified by 2′-O-methylation, which effectively stabilized them against plasma
endonucleases, while preserving their ability to trigger the RNAi silencing machinery. Oligonucleotides
with this stabilizing modification have a relatively low affinity for albumin and other plasma proteins ,
thus diminishing their distribution to the liver and facilitating renal clearance/uptake.
Several aspects of the data presented here enhance the potential clinical application of siRNA for kidney-
related processes. First, the kidney and, in particular, the PTC are overwhelmingly the primary site of
tissue distribution following intravenous injection. Second, the rapid clearance from the body minimizes
exposure of other organs/cells. Third, the optimum administration time of approximately 4 h after the
initiation of reperfusion injury could enable both prophylactic treatment and rapid treatment after a
diagnosis of AKI has been made. Finally, the observed short duration of effect of siRNA in the kidney is
favorable for molecular targets such as p53 where long-term inhibition of expression may pose a safety
risk due to the cancer surveillance functions of this protein. Indeed, siRNA-mediated reduction of p53
mRNA lasted no longer than 72 h. Previous studies have demonstrated that short-term inhibition of p53
with subsequent restoration of its normal function is safe even from the standpoint of potentially
increased carcinogenicity known to be associated only with complete and permanent p53 loss.
Altogether, the above observations indicate that synthetic siRNAs represent a very favorable strategy to
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Kidney injury models.
achieve short-term inhibition of p53 expression in PTC to protect against ischemic and nephrotoxic
kidney injury.
These results offer further insight into the utilization of siRNA for modulating proximal tubular cell
events with particular emphasis on the inhibition of upregulation and amplification of potentially
harmful intracellular pathways.
Concise Methods
Animals
Male Sprague-Dawley (SD) or Munich Wistar (MW) 200–250g rats were used for all studies and cared
for as described previously.  All protocols were approved by the Indiana University IACUC committee.
siRNA Sequences, Modifications and in vitro Activity Evaluation
All siRNA molecules used in this study were stabilized by alternating 2′O-methylation as described
previously  and were synthesized at BioSpring (Frankfurt, Germany). siRNA used for in situ
hybridization studies had sequence 5′- GUGCCAACCUGAUGCAGCU-3′ (sense strand). siRNAagainst
GFP was as described previously.  Active siRNA against p53 used in the in vivo studies had sequence
5′- GAAGAAAATTTCCGCAAAA-3′ (sense). Efficacy of siRNAs targeting p53 was tested in Rat1 cells
expressing endogenous p53 gene. Transfection of siRNA was performed using Lipofectamine2000
(Invitrogen, CA) according to the manufacturer's instructions. p53 knockdown was determined either
by immunoblotting with anti-p53 antibodies (Clone 240, Chemicon or OncogeneScience) or by
quantitative real-time RT-PCR (see below).
Quantitative Real-Time PCR for Determining p53 mRNA Levels
RNA was extracted from cells or tissues using EZ-RNA extraction kit (Biologic Industries, Beth
HaEmek, Israel). Following cDNA synthesis (Superscript reverse transcriptase, Invitrogen), p53mRNA
levels were evaluated using the SYBR Green procedure on an Applied Biosystems 7300 PCR machine.
p53 mRNA levels were extrapolated from the standard curve generated by the amplification of serially
diluted DNA standards of known concentrations of p53 amplicon. The measured p53 mRNA levels were
corrected for errors arising from differences in sample preparation and reverse transcription efficiencies
using the expression levels of housekeeping reference genes as internal standards, β-actin and/or
cyclophilin A mRNA. The following primers were used for RT-PCR amplification:
rat p53 forward primer – 5′-ACAGCGTGGTGGTACCGTAT-3′
rat p53 reverse primer – 5′- GGAGCTGTTGCACATGTACT- 3′
rat β-actin forward primer – 5′-AGAGCTATGAGCTGCCTGAC-3′
rat β–actin reverse primer – 5′-AATTGAATGTAGTTTCATGGATG-3′
rat cyclophilin A forward primer 5′- CGACTGTGGACAGCTCTAAT-3′
cyclophilin A reverse primer - 5′-CCTGAGCTACAGAAGGAATG-3′
PCR conditions were as follows: Step1 −50 °C 2 min; Step 2 to 95 °C 10 min; Step 3 (X40) −95 °C 15 s
followed by 60 °C 1 min; Step 4 (dissociation) was according to default “Dissociation Function” settings
programmed in the real-time PCR machine- ABI-7300.
Bilateral renal pedicle clamp for 45 min at 37° or the partial aortic clamp procedures
were performed as described previously to induce AKI.  For the partial aortic-clamp model, the
abdominal aorta just below the renal arteries was isolated through blunt dissection from the inferior
vena cava, and an ultrasonic probe (2.0 mm diameter, Transit Time Perivascular Flowmeter TS420,
Transonic Systems, Inc., Ithaca, NY) was placed and secured for precise determination of aortic flow.
The aortic clamp itself comprised two 4 mm length polyethylene tubing (PE-100, 0.86 mm diameter,
Clay Adams Co, Parsippany, NJ), one around the aorta and the second piece to exert variable tension
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via a 10 inch 3.0 silk suture. A 90% reduction of initial aortic blood flow rate was induced and measured
on the ultrasonic probe reader for duration of 60 min. A 0.15 ml venous blood sample was drawn at
study initiation for baseline creatinine measurement and at 24 h postsurgery for functional evaluation
of severity of kidney injury. Serum creatinine concentrations were measured on a Creatinine Analyzer 2
from Beckman Inc. Unless otherwise noted, studies were terminated 24 h postsurgery, and the rats
were euthanized by pentobarbital overdose followed by cervical dislocation.
To induce cisplatin injury, we utilized 7.5 mg/Kg given intraperitoneally to fasting rats. Cisplatin was
freshly prepared in sterile saline at 1 mg/ml and injected; control animals were injected with a
comparable volume of saline. Intravenous injections of normal saline, PBS, or siRNA in either of these
vehicles were made in volumes of 0.3 ml or less over 1 to 3 min via either the femoral or jugular veins.
In all studies, the untreated controls or ischemic rats received vehicle injections identical in amount and
timing as the siRNA-treated rats.
Tissue Handling, Fixation, and Histopathology
Following euthanasia, kidneys were harvested and sliced into two longitudinal parts. One part was fixed
in 4% paraformaldehyde and processed for paraffin embedding followed by histologic assessment. The
second part of each kidney was immediately, upon excision, divided into medulla and cortex portions
and snap-frozen in liquid nitrogen. It was further used for protein and RNA extraction for
immunoblotting and qPCR analysis of gene expression, respectively.
5 μm sections were prepared from paraffin-embedded renal samples and mounted on microscopic
slides. Sections were stained with hematoxylin-eosin. Slides were randomly numbered to afford “blind”
(in regard to treatment groups) evaluation. Three pathomorphological features were assessed separately
in the renal cortex and medulla: tubular necrosis, tubular dilation, and presence of tubular “casts”
(necrotic debris within the tubular lumen). Grading of pathologic changes was performed according to
the following scoring system:
Grade 0 – no pathologic changes
Grade 1 - feature involves 1 to 10% of the area
Grade 2 - feature involves 10 to 25% of the area
Grade 3 - feature involves 25 to 75% of the area
Grade 4 - feature involves more than 75% of the area
TUNEL Labeling to Quantify Apoptosis
Apoptosis in cortical or outer medullary samples was quantified utilizing techniques previously
published from our laboratory.  Tissue pieces from the fixed kidneys were preserved in 20% sucrose
before 10-um frozen sections were obtained. Sections were stained with TUNEL reagent (Promega,
Madison, WI) and DAPI for in situ apoptosis detection. In brief, 10-um frozen sections were treated
with 20 μg/ml proteinase K and then incubated in a nucleotide mixture containing fluorescein-12-dUTP
and TdT (terminal deoxynucleotidyl transferase). Positive controls were pretreated with 1 U/ml DNAse,
and negative controls were incubated without TdT. TUNEL-positive nuclei were expressed as a percent
of total nuclei (DAPI-positive) per field. Six to eight fields per section and three sections per kidney were
examined in each experiment.  Images were collected on a Zeiss LSM 510 confocal microscope and
analyzed with Zeiss LSM software and MetaMorph (Universal Imaging Corporation).
Protein Extraction and Immunoblotting Analysis
Frozen kidney samples were pulverized to a powder over liquid nitrogen and used for preparation of
protein extracts in RIPA buffer (10 mM Tris-HCL pH 7.4, 150 Mm NaCl, 1% Triton x-100, 1% sodium
deoxycholate, 0.1% SDS) containing protease inhibitors cocktail (Roche, Cat# 1 836 145). Two hundred
μg of total protein from kidney medulla or cortex samples were fractioned by electrophoresis through
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10% polyacrylamide/SDS gels. The following commercially available primary antibodies were used for
immunoblotting analysis of p53 and other protein expression: anti-p53 mouse monoclonal antibodies
(mAb240, Oncogene Science); anti-PUMA goat polyclonal antibody DO-20 (Santa Cruz
Biotechnology); anti-MDM2 rabbit polyclonal antibody SMP14 (Santa Cruz Biotechnology), anti-p21
(waf1) rabbit polyclonal antibody C-19 (Santa Cruz Biotechnology); anti-BCL2 rabbit polyclonal
antibody (Santa Cruz Biotechnology); and anti-α-Tubulin mouse monoclonal antibodies TUB-1A2
(Sigma). Corresponding secondary antibodies were purchased from Santa Cruz Biotechnology.
siRNA in situ Hybridization
The method was based on the procedure described by Nelson et al., 2006  with some modifications.
Paraffin-embedded kidney sections were deparaffinized and processed. The hybridization probe was
single-stranded oligonucleotide in which every third position had locked nucleotide (LNA). Its primary
sequence corresponded to the sense strand of intravenously injected tracer siRNA duplex. Scrambled
similarly modified sequence was used as a negative control. The oligonucleotide probes were labeled
with digoxigenin. The slides were hybridized overnight at 48 °C in hybridization buffer containing 50%
Formamide, 10% Dextran sulfate, 4xSSC, 1x Denhardt's Solution, 0.25mg/ml Salmon sperm DNA,
0.25mg/ml tRNA, and 20nM of single-stranded LNA-modified specific or scrambled hybridization
probe. Following washing in 5XSSC (30 min) and 50% formamide/2XSSC (30 min), the slides were
hybridized to anti-Dig antibodies (anti-Digoxigenin-AP, Roche, cat.11093274910). The antibodies were
developed using standard procedures provided by the manufacturer.
Multiphoton Microscopy and Image Analysis
All multiphoton imaging was conducted as previously optimized and described.  To study triply labeled
samples, the fluorescence emissions were split into three channels centered at 605, 525, and 455 nm
collected in separate photomultiplier tube detectors and displayed as pure red, green, and blue,
respectively. Stacks were collected by 1 μm optical steps into the tissue to a maximal depth of 100 μm.
Images and data-volumes were processed using Image J software (National Institutes of Health, MD,
http://rsb.info.nih.gov/ij/), Metamorph Image Processing Software (Universal Imaging-Molecular
Devices, PA), and Adobe Photoshop (Adobe, CA), as previously reported.
Endosomal and Cytosolic Quantitation of Cy3-siRNA
Using Metamorph image processing software v6.1 (Molecular Dynamics, Sunnyvale, CA) a 32 × 32
median filter with a subsample ratio of 1 was applied to the original image to generate a blurred image.
This image was then subtracted from the original image to leave only the bright endosomal staining
pattern. We used a default region size of 480 × 480 in the center of the image. Next, the center area is
thresholded so that only the bright endosomes, and no surrounding background values are highlighted.
The total integrated fluorescence values should be saved for quantitative analysis.
Cytosolic Analysis
Using Metamorph software, a background level was determined by selecting a small region devoid of
tissue or fluorescence before siRNA infusion and the average intensity noted. Next a 32 × 32 medial
filter (as in the endosomal analysis) was applied to the original image. The median filtered image was
then subtracted from the original image (raw-media). Next the resultant image was thresholded to
select gray scale values roughly between 35 to 255 in the “inclusive” mode, ensuring the cytosolic
portion was not selected (adjust accordingly); next we selected the “exclusive” mode and clipped the
data to create an 8-bit binary mask with values of either 0 or 255 (black or white, respectively). We then
divided the binary mask by 255 to generate a mask with values of 1s and 0s. To the original image, we
subtracted the average background value originally obtained. Next, we multiplied this image by the
mask with the values of 1s and 0s; the resulting image should have a 16 pixel edge around the image
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that should not be quantified. Using a default region size of 480 × 480 in the center of the image avoids
a 32 pixel edge around the image. Finally, we thresholded the center area of the image so that only the
tissue and no surrounding background values were highlighted. The total integrated fluorescence values
were saved for quantitative analysis. Both processes are best visualized when using a pseudocolor palette
to aid in discrimination of low-intensity gray scale values.
Statistical Analysis
Analytical data and graphs depicting data from quantitative analysis of Cy3-siRNA studies were
generated using Microsoft Excel (Microsoft, Redmond, WA). Values are reported as mean ± standard
error.
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Figures and Tables
Figure 1.
(A) Rapid filtration and uptake of fluorescence Cy 3-siRNA in the liv ing rat kidney  as v isualized by  2-photon
microscopy . A high resolution micrograph of the superficial renal cortex  shows various landmarks after
labeling with a 500 kD fluorescein dextran (green) and the nuclear dy e Hoecshts 33342 (cy an). (B) The nuclei of
various epithelial and vascular cell ty pes can be discerned; proximal tubules (PT); note the S1  segment (S1)
opening up into the Bowman's Space (Bow Sp) with adjacent Capillary  Loops (CL). The 500 kD dextran shows the
microvasculature seen between the PTs and outlines the CL within the glomerulus. The siRNA (seen in red)
rapidly  filters into the Bow Sp and down the S1  within seconds of infusion. (C) Within a minute after infusion,
3/26/2014 siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723992/?report=printable 13/18
binding to the subapical region of PTs occurred. (D) Subapical endosomes can be seen in the lower left PT
approximately  3 min postinjection. (E) The progression from binding to internalization is readily  seen in PTs 60
min postinfusion. A distal tubule (DT) in the lower portion exhibits no uptake of the siRNA. (F) Degradation of
the siRNA is apparent 24 h postinjection. There is a lack of residual fluorescence in PT or DTs. (Bar = 20 μm).
Figure 2.
Quantitative endosomal and cy tosolic fluorescence Cy 3-siRNA in renal proximal tubules. (A) Total endosomal
fluorescence Cy 3-siRNA. Utilizing a series of operations within imaging processing software, the inherent
differences in intensities between the high intensity  endosomal (B) and low intensity  cy tosolic (C) accumulated
Cy 3-siRNA can be used to distinguish them for quantitation. (D) The graph shows the total fluorescence
emanating from the two indiv idual pools per microscopic v iewing field. Images in (B) and (C) are shown using a
pseudocolor scale palette, which facilitates discerning low-intensity  gray  scale levels; a reference image is
prov ided in the upper right portion of the panel. (Bar = 20 μm).
Figure 3.
In situ hy bridization analy sis of siRNA localization in cortical sections 1  h (A) and 24 h (B) post IV injection.
Controls consisted of a nonspecific siRNA probe (C) and the specific probe used on kidney  sections from rats not
treated with siRNA (panel D).
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Figure 4.
siRNA to p53 inhibits p53 expression and is stable in human serum. (A) Different quantities of siP53 were
transfected into Rat1  cells using Lipofectamine2000. p53 mRNA was quantified using qPCR and IC50 was
calculated from a four-parameter sigmoidal curve where top was fixed as 100% based on p53 mRNA qPCR
values derived from mock-transfected Rat1  cells and the cells transfected with control GFP siRNA. Horizontal
axis shows siRNA concentration in nM; vertical axis shows residual p53 mRNA quantities as percentage of
control (100%). (B) Western blot showing p53 protein levels in Rat 1  cells transfected with siRNA. siRNA
targeting GFP was used as negative control. All cells were co-transfected with pCDNA3-GFP plasmid for
transfection control. Note that, unlike siP53 that elicited complete and specific elimination of p53 protein when
transfected at concentrations 0.5, 10 or 20 nM, siGFP was ineffective in producing either GFP or p53 KD at 20
nM. (C) Aliquots of 1  μg of siP53 were incubated in 20 μl of complete human serum at 37  °C for different time
intervals and then analy zed on nondenaturing 20% PAAG. Similar quantities of siP53 as well as of double-
stranded and single-stranded similarly  modified CNL RNA oligonucleotides of the same length dissolved in PBS
were used for size control.
Figure 5.
Effect of p53 siRNA treatment on kidney  function following ischemic injury . (A) Serum creatinine levels 24 h
post-ischemia in rats treated with PBS or siRNAs targeting p53 or GFP (1  mg/kg) given IV at −2 h and −0.5 h
pre-ischemia and 4 and 8 h post-ischemia. Serum creatinine levels in siP53-treated rats were statistically
significant lower than in PBS or GFP siRNA-treated rats (p < = 0.01, ANOVA). (B) Serum creatinine levels
quantified daily  post-ischemia with increasing doses of P53 siRNA given IV at 2 and 0.5 h pre-ischemia and 4
and 8 h post-ischemia. Animals receiv ing ≥1  mg/kg per injection of siRNA had serum creatinine levels
significantly  lower than in PBS-treated animals at 24 h postinjury  (P < 0.05, ANOVA). (C) Serum creatinine
levels 24 h post-ischemic injury  in rats injected with PBS or siP53. siRNA targeting p53 (12 mg/kg) was given as
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a single bolus IV injection at variable times pre- and postinjury  compared with the prev iously  used 3 mg/kgX4
protocol when the same 12 mg/kg total dose was split into four 3 mg/kg IV injections given at 2 and 0.5 h pre-
ischemia and 4 and 8 h post-ischemia. Data points statistically  different from PBS control (P < 0.01, ANOVA) are
marked with asterisks. (D) Effect of increasing dose of p53 siRNA on kidney  function when given 4 h postinjury .
In all groups, a statistically  significant decrease of serum creatinine levels was achieved (P < 0.01, ANOVA). In
all studies, data represent the mean ± SD. n = 6 for all groups in all studies.
Figure 6.
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Effect of P53 siRNA (12 mg/kg) on histology  and apoptosis at 24 h post-ischemic injury . (A) Representative
images of H&E staining of cortical and outer medullary  (OM) kidney  sections from rats following sham renal
ischemia surgery  and bilateral renal 45 min clamp ischemia treated only  with PBS or with p53 siRNA (siP53) at
4 h post clamp removal. (B) Incidence of tubular necrosis scores (for details, see Concise Methods) for both
cortical and medullary  kidney  sections from rats subjected to 45 min renal-clamp injury . Difference in kidney
necrosis incidence between siRNA and PBS-treated injured groups was statistically  significant (P < 0.01  for both
cortex  and medulla, ANOVA). (C) Evaluation of siP53 influence on apoptosis in injured kidney s. Histogram
shows the number of TUNEL positive cells per field of v iew in both cortical and outer medullary  sections from
kidney s obtained from rats subjected to 30-min renal clamp. Statistical significance was noted in both cortex
and medulla (P < 0.01, ANOVA) compared with PBS treated ischemic rats (I/R). In all studies, data represent
the mean ± SD for n = 6 for all studies.
Figure 7.
Intravenous P53 siRNA minimizes renal P53 protein increase after ischemia-reperfusion injury  v ia reduction of
p53 mRNA expression. (A) Western blot analy sis of expression of P53 and P53-dependent and P53-independent
proteins in kidney  extracts obtained 24 h post-ischemic-reperfusion injury  with or without siP53 treatment at 4
h postinjury . Each lane represents the results from an indiv idual rat. Tubulin served as the application control.
(B) Reduction of baseline p53 mRNA levels in renal cortex  and medulla following intravenous administration of
12 mg/kg siP53 to nonoperated rats. P53 mRNA and reference genes levels were evaluated by  qRT-PCR in each
indiv idual animal. Five groups of rats, each containing six  animals, were injected with a single 12 mg/kg bolus
IV dose of siP53 in 140 μl PBS. The animals were sacrificed at 3, 6, 24, 48, or 7 2 h after siRNA administration.
Ten control rats received 140 μl PBS and were sacrificed at 3 or 6 h (six  and four rats, respectively ) after
injection. Box-plot diagrams (SAS package) show distributions of natural logarithms of the ratios between p53
and reference genes mRNA expression levels [Ln(p53/ reference gene)]. The ratios for siP53-treated animals
are normalized to corresponding ratios obtained for PBS-treated animals. Dashed represents baseline p53
mRNA expression levels. Only  qRT-PCR results that passed quality  control standards (i.e., slope of the
2
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calibration curve was in the interval [−4, −3], R  >0.99, no extrapolation from the calibration curve and no
primer dimmers).
Figure 8.
2
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P53 inhibition minimizes functional AKI in hy poperfusion-induced and cisplatin nephrotoxicity  models. (A)
Serum creatinine levels in rats 24 h after partial aortic clamp. P53 siRNA was given IV 4 h after a 60 min 90%
suprarenal aortic clamp. Serum creatinine levels were significantly  lower in siP53-treated group compared with
control (P = 0.0055; unpaired t test). Data represent the mean ± SD. (B) Daily  serum creatinine levels following
single intraperitoneal 7 .5 mg/kg cisplatin injection. Lower panel. Efficacy  of siP53 in cisplatin-induced kidney
injury  model. Serum creatinine levels were measured on day  five after single intraperitoneal cisplatin (7 .5
mg/kg) administration. Groups 1  to 5 received: (1) PBS IV injection 4 h after cisplatin administration, (2) single
P53 siRNA (12mg/kg) IV injection 30 min before cisplatin administration, (3) single P53 siRNA (12 mg/kg) IV
injection 4 h after cisplatin administration, (4) three P53 siRNA (12 mg/kg each) IV injections 30 min before
and on day s two and three after cisplatin administration, and (5) three P53 siRNA (12 mg/kg each) IV injections
4 h and on day s two and three after cisplatin administration. Groups 4 and 5 showed significant reduction of
serum creatinine levels compared with control (P < 0.001, ANOVA). Data represent the mean ± SD. n = 6 for all
groups in all studies.
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